,38 To assess whether the PI3K/mTOR pathway controlled immune‐landscape in uLMS could influence immunotherapy response, we evaluated the expression of a pan‐tumour T‐cell inflamed gene signature, which reliably predicts clinical response to PD‐1 blockade in 10 different cancer types, in our cohort of (u)LMS‐TCGA samples.29 This evidence concerns the gene PDCD1 and neoplasm.